Live feed17:03:22·3hPRReleasevia QuantisnowCelcuity's Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in Progression-Free Survival in PIK3CA Mutant CohortByQuantisnow·Wall Street's wire, on your screen.CELC· Celcuity Inc.Health Care
